Home › Glioblastoma › Michigan
Glioblastoma clinical trials in Michigan
11 studies for Glioblastoma are looking for participants at sites in Michigan.
Cities in Michigan
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Henry Ford Cancer- Detroit, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- START | Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06914128Targeted Pediatric High-Grade Glioma Therapy
- C.S. Mott Children's Hospital, Ann Arbor
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Henry Ford Hospital, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06319027ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- C.S. Mott Children's Hospital, Ann Arbor
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
- Henry Ford Health System, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 16, 2025 · NCT05686798SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- University of Michigan, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Henry Ford Hospital, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.